Skip to main content
OpenTrials

Clinical trial condition

Lymphatic Diseases

Explore clinical trials studying Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

9,012 public trials 1,844 recruiting studies
Refine in advanced search Browse all conditions

Lymphatic Diseases trial results

Active, not recruiting

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

NCT03697512

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • CHU UCL Namur / site Godinne Yvoir, Belgium
  • CHU de Tours - Hôpital Bretonneau Tours, Cedex 01, France
  • CHU de Montpellier Montpellier, Cedex 05, France
  • CHU d'Estaing Clermont-Ferrand, Cedex 1, France
View all 36 locations
View Trial Details
Active, not recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

NCT04404660

Conditions
Burkitt Lymphoma, DNA Virus Infections, Disease Attributes, +19 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California San Diego Health (UCSD) La Jolla, California, United States
  • University of California Davis (UC Davis) Sacramento, California, United States
  • University of California San Francisco (UCSF) San Francisco, California, United States
View all 34 locations
View Trial Details
Active, not recruiting

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

NCT05798156

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Uniklinik Innsbruck Innsbruck, Austria
  • Kepler Universitätsklinikum Linz, Austria
  • Ordensklinikum Linz - Barmherzige Schwestern Linz, Austria
  • Ordensklinikum Linz - Elisabethinen Linz, Austria
View all 28 locations
View Trial Details
Active, not recruiting

Study of Acalabrutinib and Tafasitamab in MZL Patients

NCT04646395

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Wien Vienna, Austria
  • ASST Spedali Civili di Brescia Brescia, Italy
  • Fondazione IRCCS - Istituto Nazionale dei Tumori Milan, Italy
  • Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico Milan, Italy
View Trial Details
Active, not recruiting

9-ING-41 in Patients With Advanced Cancers

NCT03678883

Conditions
Acute T Cell Leukemia Lymphoma, Bone Cancer, Bone Diseases, +90 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • Arizona Oncology Associates Tucson, Arizona, United States
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • University of California Irvine Health Orange, California, United States
View all 66 locations
View Trial Details

Related conditions